• Explore /
  • Poster
  • / CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

Abstract Poster

Authors

Leora Horn

Leora Horn

Vanderbilt University Medical Center, Nashville, TN

Leora Horn , Martin Reck , Scott N. Gettinger , David R. Spigel , Scott Joseph Antonia , Brent A. Rupnow , Anne Pieters , Giovanni Selvaggi , Justin P. Fairchild , Solange Peters

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02481830

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS8578)

DOI

10.1200/JCO.2016.34.15_suppl.TPS8578

Abstract #

TPS8578

Poster Bd #

202a

Abstract Disclosures

Similar Posters

First Author: Neal Ready

First Author: Luis G. Paz-Ares

First Author: Alejandro Navarro

First Author: Anne C. Chiang